127 related articles for article (PubMed ID: 18429949)
1. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review.
Acharya SH; Avenell A; Philip S; Burr J; Bevan JS; Abraham P
Clin Endocrinol (Oxf); 2008 Dec; 69(6):943-50. PubMed ID: 18429949
[TBL] [Abstract][Full Text] [Related]
2. A comparison of cardiovascular disease, cancer, mortality, and Graves' ophthalmopathy following treatment for hyperthyroidism: A Bayesian network meta-analysis.
Liu X; Wong CKH; Wu T; Chan WWL; Woo YC; Lam CLK; Lang BHH
World J Surg; 2024 Feb; 48(2):393-407. PubMed ID: 38686801
[TBL] [Abstract][Full Text] [Related]
3. TSH receptor autoantibody levels post-total thyroidectomy in Graves' ophthalmopathy: a meta-analysis.
Anees A; Ayeni FE; Eslick GD; Edirimanne S
Langenbecks Arch Surg; 2023 Oct; 408(1):415. PubMed ID: 37870639
[TBL] [Abstract][Full Text] [Related]
4. Serum selenium status in Egyptians patients who had Graves' disease with and without ophthalmopathy.
Hasanin GA; Mohamed MS; Maher MM; Ahmed AM; ALi HM; Mansour HK
Egypt J Immunol; 2024 Jan; 31(1):133-142. PubMed ID: 38224470
[TBL] [Abstract][Full Text] [Related]
5. Cancer Risk in Graves Disease with Radioactive
Kim KJ; Choi J; Kim KJ; Song E; Yu JH; Kim NH; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG
J Nucl Med; 2024 May; 65(5):693-699. PubMed ID: 38548348
[TBL] [Abstract][Full Text] [Related]
6. Graves' ophthalmopathy.
Bahn RS
N Engl J Med; 2010 Feb; 362(8):726-38. PubMed ID: 20181974
[TBL] [Abstract][Full Text] [Related]
7. The two-year results of using radiofrequency ablation as a novel treatment for persistent or relapsed Graves' disease, a prospective study.
Fung MHM; Luk Y; Yuen KK; Lang BHH
Thyroid; 2024 Jun; ():. PubMed ID: 38836419
[TBL] [Abstract][Full Text] [Related]
8. An Appraisal of the Preventive Effect of Statins on the Development of Graves' Ophthalmopathy: A Hospital-Based Cohort Study.
Hsu GC; Shih SR; Chang FY; Liao SL; Wei YH
Ophthalmol Ther; 2024 Jun; 13(6):1499-1511. PubMed ID: 38581604
[TBL] [Abstract][Full Text] [Related]
9. Combined glucocorticoids and cyclophosphamide in the treatment of Graves' ophthalmopathy: a systematic review and meta-analysis.
Xiang Q; Yang M; Luo W; Cao Y; Shuai S; Wei X; Xiong A
BMC Endocr Disord; 2024 Jan; 24(1):12. PubMed ID: 38273269
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease.
Ueland GÅ; Ueland HO; Stokland AM; Bhan A; Schønberg A; Sollid ST; Morgas DE; Holmøy T; Lima K; Methlie P; Løvås K; Torkildsen Ø; Husebye ES
J Clin Endocrinol Metab; 2024 Jan; 109(2):344-350. PubMed ID: 37708353
[TBL] [Abstract][Full Text] [Related]
11. Regression of Ophthalmopathic Exophthalmos in Graves' Disease After Total Thyroidectomy: a Prospective Study of a Surgical Series.
Bhargav PRK; Sabaretnam M; Kumar SC; Zwalitha S; Devi NV
Indian J Surg; 2017 Dec; 79(6):521-526. PubMed ID: 29217903
[TBL] [Abstract][Full Text] [Related]
12. The need for the GREAT+ score to predict relapse in Graves' disease: a questionnaire among patients and internal medicine specialists.
Jansen HI; Heuveling van Beek C; Bisschop PH; Heijboer AC; Bruinstroop E; Boelen A
J Endocrinol Invest; 2024 Mar; ():. PubMed ID: 38526836
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and immunological predictors of Graves' orbitopathy after radioiodine therapy of Graves' disease].
Sheremeta MS; Bessmertnaya EG; Elfimova AR; Babaeva DM; Belovalova IM; Sviridenko NY
Probl Endokrinol (Mosk); 2023 Nov; 69(5):16-24. PubMed ID: 37968948
[TBL] [Abstract][Full Text] [Related]
14. The Relationship between Obesity-Related Factors and Graves' Orbitopathy: A Pilot Study.
Lu C; Lai CL; Yang CM; Liao KC; Kao CS; Chang TC; Perng MD
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556950
[No Abstract] [Full Text] [Related]
15. Current concepts regarding Graves' orbitopathy.
Bartalena L; Tanda ML
J Intern Med; 2022 Nov; 292(5):692-716. PubMed ID: 35604323
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'.
Sjölin G; Byström K; Holmberg M; Törring O; Khamisi S; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Planck T; Wallin G
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00244. PubMed ID: 34277969
[TBL] [Abstract][Full Text] [Related]
17. Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma.
Murayama D; Toda S; Okubo Y; Hayashi H; Matsui A; Yasukawa M; Iwasaki H
Case Rep Endocrinol; 2021; 2021():3024639. PubMed ID: 34221517
[TBL] [Abstract][Full Text] [Related]
18. Combination Model of Thyrotrophin Receptor Antibody and Volumetric Orbital Apex Crowding Index as an Indicator of Dysthyroid Optic Neuropathy.
Deng Z; Chen L; Tan J; Wang S; Liu D; Wang J; Jiang C; Yang J; Xu B
Dis Markers; 2021; 2021():9964232. PubMed ID: 34113406
[TBL] [Abstract][Full Text] [Related]
19. The change in the clinical presentation of Graves' disease: a 30 years retrospective survey in an academic Brazilian tertiary center.
Pinto W; Romaldini JH; Perini N; Santos RB; Villagelin D
Arch Endocrinol Metab; 2021 May; 64(5):514-520. PubMed ID: 34033290
[TBL] [Abstract][Full Text] [Related]
20. A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
Farag S; Feeney C; Lee V; Nagendran S; Jain R; Aziz A; Akishar R; Bravis V; Meeran K
Front Endocrinol (Lausanne); 2021; 12():669871. PubMed ID: 34025584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
